Bristol-Myers Wins Patent Fight Over Generic HIV Drug

Law360, Los Angeles (November 5, 2013, 9:11 PM EST) -- A Delaware federal judge on Tuesday handed victory to Bristol-Myers Squibb Co. in its battle to assert its patent on its HIV treatment Sustiva against generic drugmakers Mylan Pharmaceuticals Inc. and Matrix Laboratories Ltd., finding a generic version of the drug would infringe the patent.

Bristol-Myers, which markets and sells Sustiva in 600-milligram efavirenz tablets, filed the suit in August 2010 after the generic-drug makers filed an abbreviated new drug application asking for approval to make and sell a generic version of Sustiva for HIV type...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.